Trial Profile

Phase I Open Label Multicenter Dose Escalation Study of the Safety and Pharmacokinetics of ME-143 as a Single Agent in Patients With Refractory Solid Tumors.

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 07 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ME 143 (Primary)
Indications Solid tumours
Focus Adverse reactions; Pharmacokinetics; Therapeutic Use

Most Recent Events

04 Jun 2012 Status changed from active, no longer recruiting to completed.
03 Apr 2012 Results will be reported at the 2012 American Society of Clinical Oncology (ASCO) Annual Meeting, according to a Marshall Edwards media release.
03 Apr 2012 Status changed from recruiting to active, no longer recruiting, according to a Marshall Edwards media release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com